Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

28 Jun 2019 07:00

RNS Number : 7219D
DeepMatter Group PLC
28 June 2019
 

28 June 2019

DeepMatter Group plc

("DeepMatter", the "Company" or the "Group")

 

Directorate Change

 

As previously announced, DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitizing chemistry, is pleased to confirm the appointment of Lauren Lees to the Board as Financial Director with immediate effect.

 

Lauren is a chartered accountant who qualified with Grant Thornton UK LLP and has been Financial Controller at the Company since October 2018, during which time she has played a significant role in the strategic and operational development of the Group. Previously, she was Financial Controller at BioOutsource Limited, a high growth start-up life science company which was acquired by Sartorius AG in 2015, and then rebranded as Sartorius Stedim BioOutsource Limited, serving on both the local management and strategy teams. Lauren takes over as Financial Director from Michael Bretherton who has stepped down with immediate effect.

 

Lauren Rachel Lees, aged 31, holds no other current directorships, nor has she held a directorship during the five years prior to her appointment. She holds no interest in ordinary shares of the Company. There are no further disclosures to be made in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

Mark Warne, Chief Executive Officer of DeepMatter, commented: 

 

"We are grateful for the significant contribution Michael has made to the business and wish him well in his future endeavours. We are also pleased to welcome Lauren to her new role as Financial Director. Her positive influence on not only the finance department, but also the broader Group so far has been significant, and we look forward to benefitting from her skills and experience further at Board level."

 

Ends

 

 

For further information:

 

DeepMatter Group plc

T: 0141 548 8156

Mark Warne, Chief Executive Officer

 

 

 

Shore Capital (Nominated Adviser and Broker)

T: 020 7601 6100

Tom Griffiths

David Coaten

 

 

 

Alma PR

Caroline Forde

Susie Hudson

Jessica Joynson

 

T: 020 3405 0209

deepmatter@almapr.co.uk

 

About DeepMatter:

 

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. In the near term this involves the provision of an integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware™, to scientists across research and process development sectors.

 

The DigitalGlassware™ platform allows chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. The platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAPGUCAQUPBGAM
Date   Source Headline
13th Apr 20167:00 amRNSPreliminary Results
21st Oct 20157:00 amRNSCompletion of Capital Reorganisation
7th Oct 20151:56 pmRNSResult of Court Hearing
29th Sep 20153:33 pmRNSHolding(s) in Company
28th Sep 201510:02 amRNSHolding(s) in Company
16th Sep 20157:00 amRNSChange of Name
15th Sep 20153:32 pmRNSHolding(s) in Company
15th Sep 201510:02 amRNSDirectors' Interest in Shares
15th Sep 201510:01 amRNSDirectorate Changes
15th Sep 201510:00 amRNSCompletion of Placing and Acquisition
11th Sep 201510:00 amRNSApplication for Admission
10th Sep 201511:16 amRNSResult of General Meeting
25th Aug 20155:10 pmRNSHalf Yearly Report
25th Aug 20155:05 pmRNSAcquisition and related matters
7th Jul 20157:00 amRNSChange of Name
30th Jun 201512:10 pmRNSResult of AGM
4th Jun 20158:35 amRNSReplacement: Final Results
4th Jun 20157:00 amRNSDirectorate Change
4th Jun 20157:00 amRNSFinal Results
8th Jan 20155:56 pmRNSHolding(s) in Company
9th Sep 20147:00 amRNSCompletion of investment in subsidiary
29th Aug 20147:00 amRNSHalf Yearly Report
14th Jul 201411:00 amRNSResult of AGM
30th Jun 20147:00 amRNSFirst commercial sale
17th Jun 20147:00 amRNSFinal Results
17th Mar 20147:00 amRNSGraphene Functionalisation Capabilities
3rd Feb 20147:00 amRNSProject Announcement
24th Jan 20147:00 amRNSOAS launches OntoTM Development Pack for customer
18th Nov 20135:43 pmRNSHolding(s) in Company
30th Oct 20137:00 amRNSDirectorate Change
18th Oct 20137:00 amRNSChange to substantial shareholdings
20th Sep 20137:00 amRNSDirectorate Change
28th Aug 20139:40 amRNSHalf Yearly Report
13th Jun 20135:30 pmRNSAGM Statement
1st May 20137:00 amRNSFinal Results
12th Apr 20131:10 pmRNSHolding(s) in Company
13th Mar 20138:42 amRNSHolding(s) in Company
12th Mar 20138:37 amRNSHolding(s) in Company
6th Mar 20134:03 pmRNSHolding(s) in Company
9th Jan 20137:00 amRNSTechnical Advisory Board Enhanced
7th Jan 20134:25 pmRNSHolding(s) in Company
20th Dec 20121:55 pmRNSHolding(s) in Company
5th Dec 20125:33 pmRNSHolding(s) in Company
12th Nov 20128:51 amRNSHolding(s) in Company
3rd Oct 20127:00 amRNSDirectors' Interest in Shares
26th Sep 20127:00 amRNSInterim Statement
24th Sep 20129:58 amRNSHolding(s) in Company
17th Sep 20129:26 amRNSHolding(s) in Company
1st Aug 20127:00 amRNSAppointment of CEO
15th Jun 201212:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.